Business Wire

STAAR Surgical Announces Preliminary Net Sales Results for Third Quarter 2025

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, ...
Seeking Alpha

STAAR Surgical Surpasses 4 Million ICLs Sold Globally, Reflecting Ongoing Shift Away from Laser-Based Vision Correction

LAKE FOREST, Calif.--(BUSINESS WIRE)-- STAAR Surgical Company (STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today ...
Healio

FDA expands age indication for EVO ICL

Please provide your email address to receive an email when new articles are posted on . The EVO ICL is now approved for use in patients between the ages of 21 to 60 years. Clinical trial data ...
Hosted on MSN

STAAR Surgical projects significant China revenue rebound in Q3 2025 amid tariff mitigation and new product launch

CEO Stephen Farrell highlighted efforts to return STAAR to sustainable growth, addressing short-term issues like channel inventory, cost discipline, and tariffs. He emphasized the ongoing strength of ...
Morningstar

FDA Expands U.S. Age Indication for EVO ICL as Long-Term Safety Data Reinforces Market Shift Away From Laser Vision Correction

FDA Expands U.S. Age Indication for EVO ICL as Long-Term Safety Data Reinforces Market Shift Away From Laser Vision Correction New FDA expansion of U.S. age indication extends EVO ICL use for patients ...